The International Association for the Study of Lung Cancer’s World Conference on Lung Cancer from 7 to 10 September in San Diego will showcase the increased focus on targeted therapies, including rising interest in bispecific T-cell engagers (BiTEs) and antibody-drug conjugates (ADCs), in lung cancers.
Key Takeaways
-
The World Conference on Lung Cancer (WCLC) meeting 7-10 September in San Diego will highlight new directions in treatment, including antibody-drug conjugates and bispecifics.